NCT05986084View on ClinicalTrials.gov

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana

PHASE4RecruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Pre-Exposure Prophylaxis (PrEP)Breast Feeding

Interventions

DRUG

Cabotegravir Injection [Apretude]

Injection

Trial Locations (2)

02215

NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center, Boston

Unknown

RECRUITING

Botswana Harvard AIDS Institute Partnership, Gaborone

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

Botswana Harvard AIDS Institute Partnership

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

ViiV Healthcare

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER